This invention relates to compounds of Formula (I) wherein Cy.sup.1, L.sup.1, Y, R.sup.1, L.sup.2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions. ##STR00001##

Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R.sub.1, R.sub.2, R.sub.3, R.sub.101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections. ##STR00001##

Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R.sub.1, R.sub.2, R.sub.3, R.sub.101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections. ##STR00001##

Compounds of formula (I) inhibit HDAC activity: ##STR00001##
wherein A, B and D independently represent ═C— or ═N—; W is a divalent radical —CH═CH— or CH.sub.2CH.sub.2—; R.sub.1 is an ester group; R.sub.2 is the side chain of a natural or non-natural alpha-amino acid; z is 0 or 1; and Y, L.sup.1, and X.sup.1 are as defined in the claims.

Compounds of formula (I) inhibit HDAC activity: ##STR00001##
wherein A, B and D independently represent ═C— or ═N—; W is a divalent radical —CH═CH— or CH.sub.2CH.sub.2—; R.sub.1 is an ester group; R.sub.2 is the side chain of a natural or non-natural alpha-amino acid; z is 0 or 1; and Y, L.sup.1, and X.sup.1 are as defined in the claims.

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-γ-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-γ-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

The compounds of the present invention are represented by the following compounds having Formula I: ##STR00001##
where the substituents R.sup.1, R.sup.4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): ##STR00002##
where the substituents R.sup.1-R.sup.4, R.sup.x, R.sup.y, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

The compounds of the present invention are represented by the following compounds having Formula I: ##STR00001##
where the substituents R.sup.1, R.sup.4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): ##STR00002##
where the substituents R.sup.1-R.sup.4, R.sup.x, R.sup.y, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain and fever.